UNSPSC 51402309: Mepiprazole dihydrochloride

This classification denotes an antidepressant agent with the molecular formula C16H21ClN4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN5WJ92YGP, chemically known as piperazine, 1-(3-chlorophenyl)-4-(2-(5-methyl-1h-pyrazol-3-yl)ethyl)-, hydrochloride (1:2), but more generally known as mepiprazole dihydrochloride, which bears US NIH Compound Identifier 209757. European Medicines Agency schedules mepiprazole dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08751MIG.

Most nations, for tariff purposes, schedule mepiprazole dihydrochloride under HS 29335995. SMILES: CC1CC(N[NH]1)CCN2CCN(CC2)C3CCCC(C3)CL.CL.CL.

UNSPSC 51402309 Mepiprazole dihydrochloride is a Commodity code that represents a specific pharmaceutical active ingredient, yet recent state and local procurement activity tagged to this code does not reflect purchases of mepiprazole dihydrochloride itself. Instead, the opportunities posted under this code involve naloxone, safe drug deactivation systems, and broader multi-source generic pharmaceuticals and over-the-counter products — indicating a mismatch between the code's nominal scope and the work state and local governments are actually buying. State and local health agencies and cooperative purchasing alliances are the primary issuing bodies, with solicitations spanning health departments, county community health initiatives, state health commissions, and multistate purchasing consortia. The work being solicited centers on pharmaceutical products and medical countermeasures for community health support, with payment structures ranging from fixed-fee competitive bids to cooperative purchasing agreements with authorized wholesalers.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, through competitive sealed bidding); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. (proposals due March 26, 2026). Activity is concentrated in Florida and Texas, with multistate reach through MMCAP's cooperative vehicle serving Minnesota, Oregon, and participating jurisdictions. The code shows inconsistent recent activity aligned to its stated scope; business development professionals should verify that opportunities posted under 51402309 reflect genuine mepiprazole dihydrochloride procurement rather than relying on the code assignment alone.